The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 334-341

  Akpek, Mahmut ^a   Kaya, Mehmet G ^a   Uyarel, Huseyin ^b   Yarlioglues, Mikail ^a   Kalay, Nihat ^a   Gunebakmaz, Ozgur ^a   Dogdu, Orhan ^a   Ardic, Idris ^a   Elcik, Deniz ^a   Sahin, Omer ^a   Oguzhan, Abdurrahman ^a   Ergin, Ali ^a   Gibson, Charles M ^c  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b BALIKESIR UNIVERSITY   (Turkey)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Primary percutaneous coronary intervention; ST elevation myocardial infarction; Uric acid

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; HEPARIN; URIC ACID;

ADULT; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ASSOCIATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; C-REACTIVE PROTEIN; CORONARY CIRCULATION; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET COUNT; TURKEY; URIC ACID;

EID: 80054977406     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.07.021     Document Type: Article

References (42)

1. The GUSTO Angiographic Investigators, The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329(November (22)):1615-22.
2. Kaya M.G., Arslan F., Abaci A., van der Heijden G., Timurkaynak T., Cengel A. Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiol 2007, 62(October (5)):445-451.
3. Ito H., Maruyama A., Iwakura K., et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996, 93(January (2)):223-228.
4. Yarlioglues M., Kaya M.G., Ardic I., et al. Relationship Between Mean Platelet Volume Levels and Subclinical Target Organ Damage in Newly Diagnosed Hypertensive Patients November 24, 2010, Blood Press.
5. Huczek Z., Kochman J., Filipiak K.J., et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005, 46(July (2)):284-290.
6. Pereg D., Berlin T., Mosseri M. Mean platelet volume on admission correlates with impaired response to thrombolysis in patients with ST-elevation myocardial infarction. Platelets 2010, 21(2):117-121.
7. Magadle R., Hertz I., Merlon H., Weiner P., Mohammedi I., Robert D. The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty. Clin Cardiol 2004, 27(March (3)):163-168.
8. Tomoda H., Aoki N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am Heart J 2000, 140(August (2)):324-328.
9. Celik T., Iyisoy A., Kursaklioglu H., et al. The impact of admission C-reactive protein levels on the development of poor myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Coron Artery Dis 2005, 16(August (5)):293-299.
10. Hong Y.J., Jeong M.H., Choi Y.H., et al. Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction. J Cardiol 2009, 54(August (1)):36-44.
11. Many A., Hubel C.A., Roberts J.M. Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol 1996, 174(January (1 Pt 1)):288-291.
12. Kato M., Hisatome I., Tomikura Y., et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005, 96(December (11)):1576-1578.
13. Erdogan D., Gullu H., Caliskan M., et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005, 59(November (11)):1276-1282.
14. Erdogan D., Gullu H., Caliskan M., et al. Coronary flow reserve and coronary microvascular functions are strongly related to serum uric acid concentrations in healthy adults. Coron Artery Dis 2006, 17(February (1)):7-14.
15. Yildiz A., Yilmaz R., Demirbag R., Gur M., Bas M.M., Erel O. Association of serum uric acid level and coronary blood flow. Coron Artery Dis 2007, 18(December (8)):607-613.
16. Freedman D.S., Williamson D.F., Gunter E.W., Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995, 141(April (7)):637-644.
17. Culleton B.F., Larson M.G., Kannel W.B., Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131(July (1)):7-13.
18. TIMI Study Group, The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985;312(April (14)):932-6.
19. Rezkalla S.H., Dharmashankar K.C., Abdalrahman I.B., Kloner R.A. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 2010, 23(October (5)):429-436.
20. Niccoli G., Marino M., Spaziani C., Crea F. Prevention and treatment of no-reflow. Acute Card Care 2010, 12(September (3)):81-91.
21. Niccoli G., Lanza G.A., Spaziani C., et al. Baseline systemic inflammatory status and no-reflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007, 117(May (3)):306-311.
22. Rezkalla S.H., Kloner R.A. No-reflow phenomenon. Circulation 2002, 105(February (5)):656-662.
23. Topsakal R., Kaya M.G., Karakaya E., et al. Relationship between no-reflow phenomenon and serotonin levels in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous intervention. Anadolu Kardiyol Derg 2010, 10(June (3)):253-259.
24. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(March (9)):1135-1143.
25. Kaya M.G., Yarlioglues M., Gunebakmaz O., et al. Platelet activation and inflammatory response in patients with non-dipper hypertension. Atherosclerosis 2010, 209(March (1)):278-282.
26. Cameron H.A., Phillips R., Ibbotson R.M., Carson P.H. Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983, 287(August (6390)):449-451.
27. Van der Loo B., Martin J.F. A role for changes in platelet production in the cause of acute coronary syndromes. Arterioscler Thromb Vasc Biol 1999, 19(March (3)):672-679.
28. Estévez-Loureiro R., Salgado-Fernández J., Marzoa-Rivas R., et al. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2009, 124(November (5)):536-540.
29. Caymaz O. Chronic heart failure and uric acid. Türk J Cardiol 2006, 9:110-114.
30. Saugstad O.D. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 1996, 98(July (1)):103-107.
31. Romano M., Buffoli F., Tomasi L., et al. The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. J Cardiovasc Med (Hagerstown) 2008, 9(January (1)):59-63.
32. Pohl U., Busse R. Endothelium-dependent modulation of vascular tone and platelet function. Eur Heart J 1990, 11(April (Suppl. B)):35-42.
33. Parent R., Paré R., Lavallée M. Contribution of nitric oxide to dilation of resistance coronary vessels in conscious dogs. Am J Physiol 1992, 262(January (1 Pt 2)):H10-H16.
34. Khosla U.M., Zharikov S., Finch J.L., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67(May (5)):1739-1742.
35. Farquharson C.A., Butler R., Hill A., Belch J.J., Struthers A.D. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002, 106(Jul (2)):221-226.
36. Bickel C., Rupprecht H.J., Blankenberg S., et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002, 89(January (1)):12-17.
37. Bos M.J., Koudstaal P.J., Hofman A., Witteman J.C., Breteler M.M. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006, 37(June (6)):1503-1507.
38. Lazzeri C., Valente S., Chiostri M., Sori A., Bernardo P., Gensini G.F. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol 2010, 138(January (2)):206-209.
39. Schmidt W.G., Sheehan F.H., von Essen R., Uebis R., Effert S. Evolution of left ventricular function after intracoronary thrombolysis for acute myocardial infarction. Am J Cardiol 1989, 63(March (9)):497-502.
40. Aquaro G.D., Pingitore A., Strata E., et al. Relation of pain-to-balloon time and myocardial infarct size in patients transferred for primary percutaneous coronary intervention. Am J Cardiol 2007, 100(July (1)):28-34.
41. Zijlstra F., Patel A., Jones M., et al. Clinical characteristics and outcome of patients with early (<2h), intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002, 23(April (7)):550-557.
42. Cannon C.P., Gibson C.M., Lambrew C.T., et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000, 283(June (22)):2941-2947.